Breaking News: Scilex Holding Company Successfully Closes $17 Million Registered Direct Offering!
Exciting News from Scilex Holding Company
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) —
Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing, and commercializing the treatment for neurodegenerative and cardiometabolic diseases, and non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering. This offering included an aggregate of 26,355,347 shares of its common stock, par value $0.0001 per share, pre-funded warrants to purchase up to an aggregate of 2,401,132 shares of common stock, and common warrants to purchase up to an aggregate of 57,512,958 shares of common stock.
The shares of common stock and accompanying common warrants (two accompanying warrants for each share of common stock) were sold at a combined offering price of $0.59 per share. Additionally, the pre-funded warrants and accompanying common warrants (two accompanying warrants for each pre-funded warrant to purchase one share of common stock) were sold at a combined offering price of $0.5899 per pre-funded warrant. All of the shares of common stock, pre-funded warrants, and accompanying common warrants sold in the offering were sold directly by Scilex.
Scilex Holding Company has been making waves in the medical industry with its focus on innovative treatments for serious health conditions. This successful offering will provide the company with the financial resources needed to continue its research and development efforts, bringing new therapeutic options to patients in need.
How Will This News Affect Me?
As a potential investor, this announcement may pique your interest in Scilex Holding Company. The successful closing of the registered direct offering indicates confidence in the company’s future prospects and growth potential. If you are considering investment opportunities in the healthcare sector, Scilex may be a company worth exploring further.
How Will This News Affect the World?
The advancements and developments made by companies like Scilex Holding Company have the potential to impact the world by offering new solutions for treating neurodegenerative and cardiometabolic diseases, as well as providing non-opioid pain management options. By investing in research and innovation, companies like Scilex contribute to the improvement of global healthcare outcomes and the overall quality of life for patients worldwide.
Conclusion
In conclusion, the successful closing of the $17 million registered direct offering by Scilex Holding Company is a significant milestone for the company and the medical industry as a whole. This financial boost will allow Scilex to further its mission of developing innovative treatments and therapies for complex health conditions, ultimately benefiting both investors and patients in need of advanced medical solutions.
